Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in DAA Treatment-Experienced Patients With Chronic Hepatitis C Genotype 1 in Russian Federation (CHOICE)
Latest Information Update: 29 Sep 2022
Price :
$35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CHOICE
- Sponsors AbbVie
- 23 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Planned primary completion date changed from 14 Dec 2021 to 28 Sep 2022.
- 01 Mar 2022 Status changed from recruiting to active, no longer recruiting.